

A NOVEL BLOOD TEST
FOR THE EARLY
DIAGNOSIS OF
ENDOMETRIOSIS

Promarker[®]Endo

powered by Proteomics International



Identifies endometriosis at all stages with high accuracy

Over 1,000 patients studied

Early screening could rule in or out the need for invasive surgery

Endometriosis



- Common and often painful disease where endometrial-like tissue grows into other organs



- Affects 1 in 9 women and girls
- Diagnosis takes an average of 7 years
- Major cause of female infertility, and individuals can suffer from intense and chronic pain which substantially impacts quality of life¹



- Annual costs estimated at up to \$9.7B in Australia², £8.2B in the UK³ and USD \$119B in the USA⁴ in loss of work and healthcare costs

Current Diagnosis

- Gold-standard is laparoscopy with histological verification by a pathologist - invasive and costly
- 50% of stage 1 endometriosis cases are missed in surgical diagnosis - most prevalent stage⁵



Significant time and cost to patients with repeated doctor consults and many patients paying out of pocket for laparoscopy



A non-invasive blood test is in high demand

A NOVEL BLOOD
TEST FOR THE EARLY
DIAGNOSIS OF
ENDOMETRIOSIS

Promarker[®]Endo

powered by Proteomics International

The PromarkerEndo test shows excellent diagnostic performance
across all stages of disease⁶

The test combines the concentration of blood-based protein
biomarkers with age and BMI using a bi-model algorithm

Results from a study of 805 participants have been published in the prestigious
medical journal *Human Reproduction*⁶


Clinical Studies and Collaborations

- ✓ **Discovery** - Wesley Medical Research Biobank (n=56 samples)
- ✓ **Analytical validation** - Royal Women's Hospital and University of Melbourne (n=596 patients; incl. endometriosis confirmed by laparoscopy and symptomatic controls)
- ✓ **Validation** - Healthy volunteers (n=153 participants)
- ✓ **Clinical validation** - St John of God Subiaco Hospital Gynecological Cancer Research Group (n=241 patients)
- ✓ **Clinical validation** - University of Oxford, Nuffield Dept. of Women's and Reproductive Health (n=620 patients)

The PromarkerEndo test can distinguish healthy
individuals and symptomatic cases from
early stages of disease⁶

A prototype PromarkerEndo model achieved excellent
diagnostic performance across earlier disease stages
and achieved high accuracy in distinguishing severe
endometriosis from symptomatic controls. See the prototype
test performance across the different stages in the figure.

Please note: The test shown is under development and not yet clinically or commercially available.



REVOLUTIONISING THE DIAGNOSIS OF ENDOMETRIOSIS

Endometriosis

PromarkerEndo

Esophageal Cancer

PromarkerEso

Diabetic Kidney Disease

PromarkerD

References:

- [1] Endometriosis, World Health Organization (WHO.org)
- [2] Endometriosis Is Undervalued: A Call to Action, DOI: 10.3389/fgwh.2022.902371
- [3] Endometriosis UK, Facts and Figures (Endometriosis-UK.org)
- [4] Endometriosis, Economic burden - Australian Institute of Health and Welfare (aihw.gov.au)
- [5] Reliability of visual diagnosis of Endometriosis, DOI: 10.1016/j.jmig.2013.04.017
- [6] Identification of plasma protein biomarkers for endometriosis and the development of statistical models for disease diagnosis, DOI: 10.1093/humrep/deae278

Subscribe to updates on
PromarkerEndo



Or at:

<https://qrs.ly/t8gqbex>



Proteomics International
LABORATORIES LTD

6 Verdun Street, Perth, WA, 6009

+61 8 9389 1992

www.proteomics.com.au

[in](#) Proteomics-International

[X](#)@proteomicsi

PromarkerEndo@proteomics.com.au